Yaupon Therapeutics Inc., of Radnor, has named Steve Tullman, the former chief executive of Ception Therapeutics, as its chairman and CEO.
Yaupon's lead product is an experimental treatment for cutaneous T-cell lymphoma. The mechlorethamine gel has been granted "fast-track" status as well as "orphan drug" status by the Food and Drug Administration.
The company said in a statement that it expects to file a New Drug Application with the FDA for the product in mid-2011.
To do so, Tullman said in the statement that he would "build an experienced management team," including bringing in former Ception executives. Ception was acquired by Cephalon Inc. in April 2010.
Founded in 2002, Yaupon raised funds from BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania early on its in development. It raised $14.5 million in 2007 from investors including Vivo Ventures and Palo Alto Investors L.L.C.
Tullman succeeds Robert Alonzo, one of the founders of Yaupon.